Vanguard Group
MRNA icon

Vanguard Group’s Moderna MRNA Stock Holding History

Vanguard Group’s Portfolio MRNA Stock Details MRNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		$1.23B Buy
41,584,782
+399,487
+1% +$10.9M 0.02% 640
2025
Q3 		$1.06B Sell
41,185,295
-523,410
-1% -$14.6M 0.02% 679
2025
Q2 		$1.15B Buy
41,708,705
+1,312,192
+3% +$34.6M 0.02% 626
2025
Q1 		$1.15B Buy
40,396,513
+72,763
+0.2% +$2.58M 0.02% 602
2024
Q4 		$1.68B Buy
40,323,750
+97,536
+0.2% +$4.66M 0.03% 512
2024
Q3 		$2.69B Buy
40,226,214
+663,418
+2% +$60.9M 0.05% 376
2024
Q2 		$4.7B Buy
39,562,796
+525,924
+1% +$66.6M 0.09% 200
2024
Q1 		$4.16B Buy
39,036,872
+5,129,800
+15% +$517M 0.08% 246
2023
Q4 		$3.37B Buy
33,907,072
+6,248,623
+23% +$526M 0.07% 281
2023
Q3 		$2.86B Buy
27,658,449
+196,012
+0.7% +$21.9M 0.07% 289
2023
Q2 		$3.34B Sell
27,462,437
-64,312
-0.2% -$8.58M 0.08% 255
2023
Q1 		$4.23B Buy
27,526,749
+244,576
+0.9% +$40.3M 0.11% 179
2022
Q4 		$4.9B Sell
27,282,173
-159,985
-0.6% -$26.2M 0.13% 145
2022
Q3 		$3.25B Sell
27,442,158
-206,299
-0.7% -$31.3M 0.1% 215
2022
Q2 		$3.95B Buy
27,648,457
+610,265
+2% +$87.2M 0.11% 179
2022
Q1 		$4.66B Sell
27,038,192
-388,378
-1% -$65.4M 0.11% 174
2021
Q4 		$6.97B Buy
27,426,570
+245,159
+0.9% +$71.7M 0.16% 106
2021
Q3 		$10.5B Buy
27,181,411
+6,986,507
+35% +$2.58B 0.26% 64
2021
Q2 		$4.75B Buy
20,194,904
+1,275,874
+7% +$228M 0.12% 147
2021
Q1 		$2.48B Sell
18,919,030
-4,452,825
-19% -$645M 0.07% 326
2020
Q4 		$2.44B Sell
23,371,855
-4,503,237
-16% -$456M 0.07% 299
2020
Q3 		$1.97B Buy
27,875,092
+2,249,560
+9% +$157M 0.07% 312
2020
Q2 		$1.65B Buy
25,625,532
+5,045,279
+25% +$276M 0.06% 348
2020
Q1 		$616M Buy
20,580,253
+3,261,216
+19% +$75M 0.03% 595
2019
Q4 		$339M Buy
17,319,037
+288,355
+2% +$5.12M 0.01% 1053
2019
Q3 		$271M Buy
17,030,682
+16,606,498
+3,915% +$245M 0.01% 1149
2019
Q2 		$6.21M Sell
424,184
-444,332
-51% -$9.54M ﹤0.01% 3089
2019
Q1 		$17.7M Buy
868,516
+543,516
+167% +$10.1M ﹤0.01% 2562
2018
Q4 		$4.96M Buy
+325,000
New +$5.34M ﹤0.01% 3090

Other funds holding MRNA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
TP
Theleme Partners London, United Kingdom $1.5B AUM 19.72% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Vanguard Group's MRNA Position: Q4 2025 in Review

Vanguard Group increased its Moderna (MRNA) stake by 0.97% in Q4 2025, buying an estimated $10.9M and bringing the position to 41,584,782 shares worth $1.23B. The position accounts for 0.02% of the portfolio, ranked #640.

Vanguard Group first reported a position in MRNA in Q4 2018 and has held it in 29 quarters since. The position peaked at $10.5B in Q3 2021. 672 funds tracked by Wall St. Rank hold MRNA as of Q4 2025.

  • Vanguard Group held 41,584,782 shares of Moderna worth $1.23B as of Q4 2025.
  • Vanguard Group bought 399,487 Moderna shares in Q4 2025, an estimated $10.9M.
  • Moderna made up 0.02% of Vanguard Group's portfolio in Q4 2025, its #640 holding.
  • Vanguard Group first reported a position in Moderna in Q4 2018 and has held it in 29 quarters since.
  • Vanguard Group's Moderna position peaked at $10.5B in Q3 2021.
  • 672 funds tracked by Wall St. Rank held Moderna as of Q4 2025.

Based on Vanguard Group's 13F filing for Q4 2025, filed 29 Jan 2026.